Immunology insights into cardiac allograft rejection

Reviews in Cardiovascular Medicine

Volumn 12, Issue 2, 2011, Pages

  Savasta, Marcello ^a   Lentini, Salvatore ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Complications; Coronary artery pathology; Heart transplantation; Immunology; Pharmacology; Physiology; Rejection; Surgery

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; FINGOLIMOD; IMMUNOGLOBULIN M ANTIBODY; LYMPHOCYTE ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MANITIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL PAIN; ACUTE GRAFT REJECTION; ACUTE VASCULAR REJECTION; ALOPECIA; ANEMIA; ANGIOCARDIOGRAPHY; ANTIGEN PRESENTING CELL; ARTHRALGIA; BLOOD VESSEL SHUNT; BONE MARROW DEPRESSION; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CARDIOVASCULAR MAGNETIC RESONANCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CHRONIC GRAFT REJECTION; CLINICAL TRIAL (TOPIC); CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIAGNOSTIC IMAGING; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG DOSE REDUCTION; EDEMA; FEVER; GASTROINTESTINAL HEMORRHAGE; GENE EXPRESSION; GINGIVA HYPERPLASIA; GLAUCOMA; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HEART TRANSPLANTATION; HEPATITIS; HUMAN; HYDROCEPHALUS; HYPERACUTE GRAFT REJECTION; HYPERGLYCEMIA; HYPERGLYCINEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPERURICEMIA; HYPOKALEMIA; IMMUNE SYSTEM; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LIVER TOXICITY; LYMPHOID ORGAN; MACROPHAGE; MORBIDITY; MORTALITY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OBSTRUCTIVE JAUNDICE; ORGAN TRANSPLANTATION; OSTEOPOROSIS; PANCREATITIS; PANCYTOPENIA; PATHOGENESIS; PEPTIC ULCER; PHENOTYPE; POSTTRAUMATIC STRESS DISORDER; PSYCHOSIS; RASH; REVIEW; SIDE EFFECT; SKIN FRAGILITY; THROMBOCYTOPENIA; TISSUE DOPPLER IMAGING; WEIGHT GAIN; ALLOTRANSPLANTATION; CORONARY ARTERY DISEASE; DRUG EFFECT; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; TREATMENT OUTCOME;

CORONARY ARTERY DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 80055099102     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3909/ricm0562     Document Type: Review

References (60)

1. Calne RY, White DJ, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet. 1978;2:1323-1327. (Pubitemid 9078430)
2. Thiel G, Bock A, Spöndlin M, et al. Long term benefits and risk of cyclosporin A (sandimmun) - an analysis at ten years. Transplant Proc. 1994;26:2493-2498.
3. Bach FH, Sachs DH. Current concepts: immunology. Transplantation immunology. N Engl J Med. 1987;317:489-492.
4. Carpentier A, Farge D. Trapianti d'organo. Rome: Il Pensiero Scientifico;1994
5. Janeway CA Jr, Golstein P. Lymphocyte activation and effector functions. Editorial overview. The role of cell surface molecules. Curr Opin Immunol. 1993;5:313-323.
6. Taylor MK, Cohen J. Cell-mediated cytotoxicity. Curr Opin Immunol. 1992;4:338-343.
7. Avery RK. Cardiac-allograft vasculopathy. N Engl J Med. 2003;349:829-830. (Pubitemid 37025401)
8. Billingham ME. Cardiac transplant atherosclerosis. Transplant Proc. 1987;19(4 Suppl 5):19-25. (Pubitemid 17151768)
9. Treasure CB, Alexander RW. Relevance of vascular biology to the ischemic syndromes of coronary atherosclerosis. Cardiovasc Drugs Ther. 1995;9(Suppl 1):13-19.
10. Libby P, Swanson SJ, Tanaka H, et al. Immunopathology of coronary arteriosclerosis in transplanted hearts. J Heart Lung Transplant. 1992;11(3 Pt 2):S5-S6.
11. Smith JD, Pomerance A, Burke M, et al. Effect of HLA matching on graft function and long-term survival after cardiac transplantation: results of a large single center study. J Heart Lung Transplant. 1995;14:S40.
12. Crisp SJ, Dunn MJ, Rose ML, et al. Antiendothelial antibodies after heart transplantation: the accelerating factor in transplant-associated coronary artery disease. J Heart Lung Transplant. 1994;13(1 Pt 1):81-91.
13. Billingham ME. Histopathology of graft coronary disease. J Heart Lung Transplant. 1992;11:S38-S44.
14. Vassalli G, Gallino A, Weis M, et al Working Group Microcirculation of the European Society of Cardiology. Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. Eur Heart J. 2003;24:1180-1188. (Pubitemid 36834633)
15. Day JD, Rayburn BK, Gaudin PB, et al. Cardiac allograft vasculopathy: the central role of ischemia-induced endothelial cell injury. J Heart Lung Transplant. 1995;14:S142-S149. (Pubitemid 26011255)
16. Ardehali A, Laks H, Drinkwater DC Jr, et al. Expression of major histocompatibility antigens and vascular adhesion molecules on human cardiac allografts preserved in University of Wisconsin solution. J Heart Lung Transplant. 1993;12(6 Pt 1):1044-1052. (Pubitemid 24017310)
17. Winters GL, Marboe CC, Billingham ME. The International Society for Heart and Lung Transplantation grading system for heart transplant biopsy specimens: clarification and commentary. J Heart Lung Transplant. 1998;17:754-760. (Pubitemid 28396984)
18. Gregory SA, Ferencik M, Achenbach S, et al. Comparison of sixty-four-slice multidetector computed tomographic coronary angiography to coronary angiography with intravascular ultrasound for the detection of transplant vasculopathy. Am J Cardiol. 2006;98:877-884. (Pubitemid 44402254)
19. Di Bella G, Lo Giudice C, Di Matteo I, et al. Acute myocarditis: from clinical presentation to cardiac imaging. Recent Patents on Medical Imaging. 2010;2:1-4.
20. Perrotta S, Lentini S, Muré P, et al. Cardiac transplant vasculopathy treated by percutaneous coronary intervention. Minerva Chir. 2008;63:321-327.
21. Angermann CE, Nassau K, Stempfle HU, et al. Recognition of acute cardiac allograft rejection from serial integrated backscatter analyses in human orthotopic heart transplant recipients. Comparison with conventional echocardiography. Circulation. 1997;95:140-150. (Pubitemid 27029955)
22. Hummel M, Dandel M, Knollmann F, et al. Long-term surveillance of heart-transplanted patients: noninvasive monitoring of acute rejection episodes and transplant vasculopathy. Transplant Proc. 2001;33:3539-3542. (Pubitemid 34042674)
23. Knosalla C, Grauhan O, Muller J, et al. Intramyocardial electrogram recordings (IMEG) for diagnosis of cellular and humoral mediated cardiac allograft rejection. Ann Thorac Cardiovasc Surg. 2000;6:89-94.
24. Pham MX, Deng MC, Kfoury AG, et al. Molecular testing for long-term rejection surveillance in heart transplant recipients: design of the Invasive Monitoring Attenuation Through Gene Expression (IMAGE) trial. J Heart Lung Transplant. 2007;26:808-814. (Pubitemid 47202072)
25. Deng MC, Eisen HJ, Mehra MR, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant. 2006;6:150-160. (Pubitemid 43382213)
26. Kato TS, Oda N, Hashimura K, et al. Strain rate imaging would predict sub-clinical acute rejection in heart transplant recipients. Eur J Cardiothorac Surg. 2010;37:1104-1110.
27. Urheim S, Edvardsen T, Torp H, et al. Myocardial strain by Doppler echocardiography. Validation of a new method to quantify regional myocardial function. Circulation. 2000;102:1158-1164.
28. Mehra MR, Uber PA, Uber WE, et al. Anything but a biopsy: noninvasive monitoring for cardiac allograft rejection. Curr Opin Cardiol. 2002;17:131-136. (Pubitemid 34457409)
29. Di Bella G, Minutoli F, Coglitore S, et al. Complications due to cardiac allograft vasculopathy and the role of imaging studies [published online ahead of print October 29, 2010]. Herz. doi:10.1007/s00059-010-3373-8.
30. Misefari A, Jirillo E. Immunopatologia. Naples: EdiSES; 1994.
31. Sellke FW, Del Nido PJ, Swanson SJ. Sabiston and Spencer's Surgery of the Chest. 7th ed. Philadelphia, PA: WB Saunders; 2005.
32. John R, Chen JM, Weinberg A, et al. Long-term survival after cardiac retransplantation: a twenty year single center experience. J Thorac Cardiovasc Surg. 1999;117:543-555. (Pubitemid 29117535)
33. Schnetzler B, Pavie A, Dorent R, et al. Heart retransplantation: a 23 year single-center clinical experience. Ann Thorac Surg. 1998;65:978-983.
34. Smith JA, Ribakove GH, Hunt SA, et al. Heart retransplantation: the 25-year experience at a single institution. J Heart Lung Transplant. 1995;14:832-839.
35. Reichart B, Meiser B, Vigano M, et al. European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results-European Tacrolimus Multicenter Heart Study Group. J Heart Lung Transplant. 1998;17:775-781. (Pubitemid 28396987)
36. Reichart B, Meiser B, Viganò M, et al. European multicenter tacrolimus heart pilot study: three year follow-up. J Heart Lung Transplant. 2001;20:249-250.
37. Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant. 1999; 18:336-345. (Pubitemid 29205269)
38. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation. 1998;66:507-515. (Pubitemid 28415379)
39. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twentythird official adult heart transplantation report 2006. J Heart Lung Transplant. 2006;25:869-879. (Pubitemid 44143013)
40. Cohn LW. Cardiac Surgery in the Adult. 3rd ed. New York, NY: McGraw-Hill; 2008.
41. Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol. 2005;56:23-46. (Pubitemid 41278644)
42. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002;277:21453-21457. (Pubitemid 34952287)
43. Kovarik JM, Schmouder R, Barilla D, et al. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol. 2004;44:532-537. (Pubitemid 38509722)
44. Tedesco-Silva H, Mourad G, Kahan BD, et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation. 2004;77:1826-1833. (Pubitemid 38822204)
45. Vanrenterghem Y, van Hooff JP, Klinger M, et al. The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Transplantation. 2004;78:9-14.
46. Savikko J, Von Willebrand E, Häyry P. Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection. Transplantation. 2003;76:455-458; discussion 471-473.
47. Pan F, Ebbs A, Wynn C, et al. FK778, a powerful new immunosuppressant, effectively reduces functional and histologic changes of chronic rejection in rat renal allografts. Transplantation. 2003;75:1110-1114. (Pubitemid 36513004)
48. Pearson TC, Alexander DZ, Winn KJ, et al. Transplantation tolerance induced by CTLA4-Ig. Transplantation. 1994;57:1701-1706. (Pubitemid 24206406)
49. Tzakis AG, Tryphonopoulos P, Kato T, et al. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation. 2004;77:1209-1214. (Pubitemid 38580299)
50. Tzakis AG, Kato T, Nishida S, et al. Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. Transplantation. 2003;75:1512-1517. (Pubitemid 36597287)
51. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance to foreign cells. Nature. 1953;172:606.
52. Womer KL, Lee RS, Madsen JC, Sayegh MH. Tolerance and chronic rejection. Philos Trans R Soc Lond B Biol Sci. 2001;356:727-738. (Pubitemid 32575704)
53. Massicot-Fisher J, Noel P, Madsen J. Recommendations of the National Heart, Lung and Blood Institute Heart and Lung Tolerance Working Group. Transplantation. 2001;72:1467-1470. (Pubitemid 33015781)
54. Madsen JC, Yamada K, Allan JS, et al. Transplantation tolerance prevents cardiac allograft vasculopathy in major histocompatibility complex class I-disparate miniature swine. Transplantation. 1998;65:304-313. (Pubitemid 28095954)
55. Masaki Y, Hirasawa A, Okuyama S, et al. Microchimerism and heart allograft acceptance. Transplant Proc. 1995;27:148-150.
56. Kubit V, Sonmez-Alpan E, Zeevi A, et al. Mixed allogeneic chimerism in lung allograft recipients. Hum Pathol. 1994;25:408-412. (Pubitemid 24151128)
57. Starzl TE, Demetris AJ, Murase N, et al. Cell migration, chimerism, and graft acceptance. Lancet. 1992;339:1579-1582.
58. Keenan RJ, Zeevi A, Banas E, et al. Microchimerism is associated with a lower incidence of chronic rejection after lung transplantation. J Heart Lung Transplant. 1994;13:S32
59. Ramsdell F, Lantz T, Faulkes BJ. A nondeletional mechanism of thymic self tolerance. Science. 1989;246:1038-1041. (Pubitemid 20010528)
60. Pinderski LJ, Kirklin JK, McGiffin D, et al. Multiorgan transplantation: is there a protective effect against acute and chronic rejection? J Heart Lung Transplant. 2005;24:1828-1833. (Pubitemid 41641859)